RxDoctor Payments Data

Francis Salazar

Internal Medicine · Pembroke Pines, FLNPI 1093923849

Payments from drug & device makers

$28,817in general payments, 2019–2025

Across 780 payments — averaging $36.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • AstraZeneca$4K
  • GSK$3K
  • Johnson & Johnson$1K
  • Sanofi-aventis U.S. LLC$1K
  • Novo Nordisk$1K
  • plus $12K from 42 others

What the payments were for

  • Speaking & faculty fees$1,3005%
  • Food & beverage$27,35295%
  • Education$1651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,817 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,553
Medicare patients
79
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$31,002
EliquisApixaban35$25,663
FarxigaDapagliflozin Propanediol28$21,447
Soliqua 100-33Insulin Glargine/Lixisenatide18$14,043
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,039
JanuviaSitagliptin Phosphate20$12,156
Xigduo XrDapaglifloz Propaned/Metformin12$10,991
JardianceEmpagliflozin17$9,968
Janumet XrSitagliptin Phos/Metformin Hcl12$6,637
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,770
Olmesartan Medoxomil28$1,585
Levothyroxine Sodium66$1,252
Rosuvastatin Calcium59$1,067
Amlodipine Besylate109$954
Omeprazole44$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,321$31,00227 claims
PfizerEliquis$820$25,66335 claims
AstraZenecaFarxiga$3,983$21,44728 claims
MerckJanuvia, Janumet Xr$229$18,79432 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,376$14,04318 claims
GSKTrelegy Ellipta$2,836$14,03916 claims
Boehringer IngelheimJardiance$595$9,96817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →